 |
|
Lean non-alcoholic fatty liver disease: Is there a place for novel antidiabetics in the therapeutic management of this underappreciated “enemy”?
Dimitrios Patoulias, Michael Doumas
Clin Mol Hepatol. 2020;26(4):582-583. Published online 2020 Sep 25 DOI: https://doi.org/10.3350/cmh.2020.0264
|
|
Citations to this article as recorded by
 Non-alcoholic fatty liver disease: Definition and subtypes
Seul Ki Han, Soon Koo Baik, Moon Young Kim
Clinical and Molecular Hepatology.2023; 29(Suppl): S5. CrossRef Comparison between obese and non-obese nonalcoholic fatty liver disease
Wah-Kheong Chan
Clinical and Molecular Hepatology.2023; 29(Suppl): S58. CrossRef
|